Veracyte, Inc. (VCYT) P/E Ratio History
Historical price-to-earnings valuation from 2024 to 2026
Loading P/E history...
VCYT Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Veracyte, Inc. (VCYT) trades at a price-to-earnings ratio of 49.7x, with a stock price of $40.76 and trailing twelve-month earnings per share of $1.08.
The current P/E is 35% below its 5-year average of 76.8x. Over the past five years, VCYT's P/E has ranged from a low of 29.9x to a high of 132.0x, placing the current valuation at the 17th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, VCYT trades at a 123% premium to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, VCYT commands a significant premium over the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our VCYT DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
VCYT P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $549M | 14.7Lowest | 1.33Best | -3% | |
| $2B | 36.3 | 4.85 | +1883%Best | |
| $21B | 25.5 | 6.01 | +171% | |
| $176B | 26.8 | 12.67 | +7% | |
| $17B | 30.5 | - | -25% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
VCYT Historical P/E Data (2024–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | $32.21 | $1.08 | 29.9x | -61% | |
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $42.10 | $0.82 | 51.6x | -33% |
| FY2025 Q3 | $34.33 | $0.38 | 91.4x | +19% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $27.03 | $0.33 | 83.0x | +8% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $29.65 | $0.41 | 72.7x | -5% |
| FY2024 Q4 | $39.60 | $0.30 | 132.0x | +72% |
Average P/E for displayed period: 76.8x
See VCYT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VCYT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare VCYT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonVCYT — Frequently Asked Questions
Quick answers to the most common questions about buying VCYT stock.
Is VCYT stock overvalued or undervalued?
VCYT trades at 49.7x P/E, below its 5-year average of 76.8x. At the 17th percentile of historical range, the stock is priced at a discount to its own history.
How does VCYT's valuation compare to peers?
Veracyte, Inc. P/E of 49.7x compares to sector median of 22.3x. The premium reflects expected growth above peers.
What is VCYT's PEG ratio?
VCYT PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2024-2026.